Maravai LifeSciences (NASDAQ:MRVI) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Maravai LifeSciences (NASDAQ:MRVI) released its quarterly earnings data on Wednesday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03, FiscalAI reports. The firm had revenue of $49.87 million for the quarter, compared to analyst estimates of $49.06 million. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 21.55%.

Here are the key takeaways from Maravai LifeSciences’ conference call:

• The company returned to positive adjusted EBITDA in Q4 with $0.536M, exceeded its cost-savings target (now > $65M annualized), and made a voluntary $50M debt repayment in Q1 2026 to reduce interest expense.
• 2026 guidance targets meaningful improvement — revenue of $200M–$210M (up 8%–13%) and adjusted EBITDA of $18M–$20M, with forecasted ~1,200 bps gross margin expansion and ~13% lower operating expenses.
• Commercial and product momentum at TriLink and Cygnus — strong demand for GMP consumables and CDMO services, early traction for ModTail and mRNA Builder, > $1.2M of GMP enzyme orders in hand for 2026, and Cygnus’s high-margin HCP kits plus growing MockV/MachV services expanding analytical offerings.
• GAAP results remain weak due to non-cash charges — Q4 GAAP net loss was $63M (including a $25.8M intangible impairment and $12.1M restructuring), full-year GAAP loss $230.8M, and Q4 operating cash outflow was $22.8M, with long-term debt of $294.2M before the voluntary repayment.

Maravai LifeSciences Price Performance

MRVI traded down $0.05 during midday trading on Friday, hitting $3.52. 795,254 shares of the company traded hands, compared to its average volume of 1,125,611. The company has a market capitalization of $898.82 million, a price-to-earnings ratio of -3.91 and a beta of 0.39. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $4.11. The business has a 50 day simple moving average of $3.43 and a two-hundred day simple moving average of $3.19. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74.

Insiders Place Their Bets

In other Maravai LifeSciences news, Director Gregory T. Lucier bought 51,472 shares of the stock in a transaction on Friday, December 5th. The shares were bought at an average price of $3.70 per share, with a total value of $190,446.40. Following the purchase, the director directly owned 106,595 shares in the company, valued at $394,401.50. This trade represents a 93.38% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantessence Capital LLC acquired a new position in Maravai LifeSciences during the third quarter worth $31,000. CIBC Bancorp USA Inc. purchased a new position in shares of Maravai LifeSciences during the 3rd quarter worth $33,000. Abel Hall LLC purchased a new position in shares of Maravai LifeSciences during the 3rd quarter worth $33,000. Insigneo Advisory Services LLC acquired a new position in shares of Maravai LifeSciences during the 4th quarter valued at about $34,000. Finally, Virtu Financial LLC purchased a new stake in shares of Maravai LifeSciences in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company increased their price target on Maravai LifeSciences from $4.00 to $4.50 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Maravai LifeSciences currently has an average rating of “Hold” and an average price target of $5.25.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.